A detailed history of Capital Fund Management S.A. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Capital Fund Management S.A. holds 71,422 shares of BPMC stock, worth $6.76 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
71,422
Previous 53,236 34.16%
Holding current value
$6.76 Million
Previous $5.74 Million 15.09%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$84.1 - $120.5 $1.53 Million - $2.19 Million
18,186 Added 34.16%
71,422 $6.6 Million
Q2 2024

Aug 13, 2024

BUY
$85.18 - $108.78 $4.53 Million - $5.79 Million
53,236 New
53,236 $5.74 Million
Q2 2023

Aug 14, 2023

SELL
$42.2 - $66.37 $4.17 Million - $6.56 Million
-98,775 Reduced 78.62%
26,860 $1.7 Million
Q1 2023

May 15, 2023

SELL
$37.97 - $50.0 $2 Million - $2.63 Million
-52,659 Reduced 29.53%
125,635 $5.65 Million
Q4 2022

Feb 13, 2023

BUY
$41.06 - $66.48 $3.1 Million - $5.02 Million
75,534 Added 73.51%
178,294 $7.81 Million
Q3 2022

Nov 14, 2022

BUY
$49.93 - $77.7 $2.09 Million - $3.26 Million
41,954 Added 69.0%
102,760 $6.77 Billion
Q2 2022

Aug 12, 2022

BUY
$45.23 - $70.15 $787,861 - $1.22 Million
17,419 Added 40.15%
60,806 $3.07 Million
Q1 2022

May 12, 2022

BUY
$54.1 - $110.08 $2.35 Million - $4.78 Million
43,387 New
43,387 $2.77 Million
Q1 2020

May 13, 2020

SELL
$48.11 - $82.22 $282,742 - $483,206
-5,877 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$66.73 - $82.59 $392,172 - $485,381
5,877 New
5,877 $471,000
Q3 2018

Nov 14, 2018

SELL
$58.91 - $78.32 $2.5 Million - $3.32 Million
-42,400 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$60.96 - $101.18 $2.58 Million - $4.29 Million
42,400 New
42,400 $2.69 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.65B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.